Krish S Krishnan sold $6.6M of KRYS
President and CEO at Krystal Biotech, Inc.. 25,000 shares at an average of $263.17, traded Mar 4, 2026, filed Mar 6, 2026.
Score components
- +25RoleCEO
- +25Trade size$6.6M at market
- 0Share of holdings soldSold 1.7% of holdings
- +15Cluster5 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +2.9%, 3m +18.6%, 6m +41.2%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001298709-26-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 4, 2026 | SOpen-market sale Common Stock10b5-1 | -483 | $257.31 | $124k | 1,499,770 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock10b5-1 | -470 | $258.38 | $121k | 1,499,300 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock10b5-1 | -1,377 | $259.87 | $358k | 1,497,923 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock10b5-1 | -3,128 | $260.49 | $815k | 1,494,795 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock10b5-1 | -2,962 | $261.41 | $774k | 1,491,833 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock10b5-1 | -2,380 | $262.44 | $625k | 1,489,453 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock10b5-1 | -2,043 | $263.70 | $539k | 1,487,410 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock10b5-1 | -8,798 | $264.85 | $2.3M | 1,478,612 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock10b5-1 | -2,439 | $265.59 | $648k | 1,476,173 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock10b5-1 | -920 | $266.56 | $245k | 1,475,253 | Mar 6, 2026 |
Related signals
Other insiders at Krystal Biotech, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 38Weak | Krystal Biotech, Inc. | Krish S Krishnan President and CEO | $9.0M 25,000 shares | -2% | |
| 33Weak | Krystal Biotech, Inc. | Suma Krishnan President, R&D | $9.0M 25,000 shares | -2% | |
| 50Moderate | KRYSsell Krystal Biotech, Inc. | Dino A Rossi director | $8.2M 25,000 shares | -33% | |
| 15Weak | Krystal Biotech, Inc. | John Charles Thomas EVP, General Counsel | $347k 1,000 shares | -100% | |
| 45Moderate | Krystal Biotech, Inc. | Krish S Krishnan President and CEO | $7.7M 25,000 shares | -2% | |
| 40Moderate | Krystal Biotech, Inc. | Suma Krishnan President, R&D | $7.7M 25,000 shares | -2% | |
| 42Moderate | Krystal Biotech, Inc. | John Charles Thomas EVP, General Counsel | $194k 642 shares | -100% | |
| 40Moderate | Krystal Biotech, Inc. | Suma Krishnan President, R&D | $6.6M 25,000 shares | -2% | |
| 40Moderate | Krystal Biotech, Inc. | Daniel Janney director | $3.3M 11,803 shares | -14% | |
| 7Weak | Krystal Biotech, Inc. | Kathryn Romano Chief Accounting Officer | $201k 750 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.